The primary patents for Xarelto (rivaroxaban) in the United States are set to expire at different times. The key composition of matter patent, U.S. Patent No. 7,250,439, expired on July 30, 2021 [1]. However, other patents protecting Xarelto remain in force, influencing its market exclusivity.
When do other Xarelto patents expire?
Additional patents covering Xarelto's use and formulation also exist. For instance, U.S. Patent No. 8,372,840, which pertains to methods of treating and preventing thrombosis, has an expiry date in 2027 [2]. Further patents related to Xarelto's manufacturing and specific formulations may extend exclusivity even beyond these dates [1][2].
How are Xarelto patents being challenged?
Patent challenges are a common strategy to bring generic alternatives to market sooner. Legal actions have been initiated against some of Xarelto's later-expiring patents. The outcome of these legal disputes can impact the exact timeline for generic competition [1][2]. DrugPatentWatch.com provides detailed information on the patent landscape and any ongoing litigation for Xarelto [1].
Can generic versions of Xarelto be approved before patent expiry?
Generic drug approval processes can run concurrently with patent challenges. If patent litigation is successful in invalidating or expiring key patents, the U.S. Food and Drug Administration (FDA) can then approve generic versions of Xarelto. The precise timing of generic entry is contingent on these patent outcomes and FDA review [1][2].
What is Xarelto used for?
Xarelto is an anticoagulant medication used to prevent and treat blood clots. It is prescribed for conditions such as preventing stroke in patients with non-valvular atrial fibrillation, treating deep vein thrombosis (DVT), and preventing blood clots after hip or knee replacement surgery [3].
What are the main competitors to Xarelto?
Xarelto belongs to a class of drugs known as direct oral anticoagulants (DOACs). Its primary competitors include other DOACs such as Eliquis (apixaban) and Pradaxa (dabigatran etexilate), as well as older anticoagulants like warfarin [3].
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/
[3] https://www.xarelto-us.com/